Multifactorial approach to predicting resistance to anthracyclines.

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Lack of validated biomarkers for anthracycline response in breast cancer.
• Estrogen receptor (ER)-negative breast cancer patients treated with anthracyclines have variable outcomes.
• Need for predictive tools to personalize neoadjuvant chemotherapy.

Purpose of the Study:

• Evaluate topoisomerase II-alpha (TOP2A) as a predictive biomarker for anthracycline response.
• Develop a gene expression signature to identify non-responders to anthracyclines.
• Assess the predictive value of TOP2A amplification and gene expression in ER-negative breast cancer.

Main Methods:

• Analysis of 149 patients from the neoadjuvant Trial of Principle (TOP) study.
• Evaluation of TOP2A gene amplification and protein expression from pre-treatment biopsies.
• Development of an anthracycline-based score (A-Score) integrating TOP2A, tumor invasion, and immune response signatures.
• Validation of the A-Score using independent datasets from EORTC 10994/BIG 00-01 and MDACC 2003-0321 trials.

Main Results:

• TOP2A amplification, not protein overexpression, significantly correlated with pathologic complete response (pCR).
• The developed A-Score demonstrated a high negative predictive value (NPV) of 0.98 in identifying patients unlikely to respond to anthracyclines.
• The A-Score's performance was independently validated across different patient subgroups and trials, showing robust NPVs.

Conclusions:

• The A-Score shows promise as a clinical tool to identify patients who will not benefit from anthracycline therapy.
• This biomarker could help spare patients from unnecessary toxicity associated with anthracycline chemotherapy.
• Further validation is warranted to establish the A-Score as a standard clinical predictive test.